# GPT 5.2 Review - Reviewer 3/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-28T15:38:45.673125
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0fc67c5d8edb8adb00697a1ecdbae0819792ef23310328af55
**Tokens:** 6500 in / 5757 out
**Response SHA256:** 287ef1331f40e65b

---

## Referee Report: *Telehealth Parity Laws and Depression Diagnosis Prevalence: Evidence from Staggered State Adoption* (Jan 28, 2026)

### Summary (what the paper does)
The paper studies whether state telehealth parity laws (private insurance coverage mandates) increased “access to mental health care,” proxied by BRFSS **lifetime** depression diagnosis prevalence (% ever told they have depression), using 2011–2019 state-year panel data and staggered adoption between 2012–2019. The main estimator is **Callaway & Sant’Anna (2021)** with not-yet-treated controls. The headline result is a small, statistically insignificant ATT of **−0.48 pp (SE 0.35)**.

The paper is competently executed as a *basic* staggered-adoption DiD exercise, but it is **not yet close** to the standard of a top general-interest journal or AEJ:EP. The biggest issues are (i) the **outcome is poorly matched** to the access mechanism and can mechanically attenuate effects, (ii) the identification strategy is thin relative to the richness of confounding policies and differential trends in mental health diagnosis, (iii) the paper is **far too short** and reads like a technical memo rather than a publishable article, and (iv) the policy coding and institutional variation (coverage vs payment parity; modalities; enforcement) are not used, which substantially weakens interpretability.

---

# 1. FORMAT CHECK

**Length**
- The manuscript provided is about **13 pages** including references (pp. 1–13). This **fails** the “at least 25 pages” expectation for top journals (excluding references/appendix). You need a full paper with appendices: policy coding appendix, event-study plots by cohort, robustness, alternative outcomes, etc.

**References / coverage**
- The bibliography is **too thin** for a paper at this level. It cites some relevant DiD and a handful of telehealth/mental health sources, but it misses several *standard* modern DiD/event-study references and much of the applied telehealth-policy evaluation literature (details in Section 4 below).

**Prose vs bullets**
- Several major sections rely on bullet lists rather than full paragraph development:
  - Section **2.3 “Limitations of Parity Laws”** (p. 4) is bullet-pointed.
  - Section **6 “Discussion”** (pp. 9–10) is largely organized as short subsections that read like extended bullet points (even where not formatted as bullets).
- At top journals, the institutional section and discussion must be written as persuasive narrative prose, not checklist-style.

**Section depth (3+ substantive paragraphs each)**
- **Introduction (Section 1, pp. 1–2):** ~3–4 paragraphs; acceptable start, but still too “report-like.”
- **Institutional Background (Section 2, pp. 3–4):** short and partially bullet-based; not 3+ substantive paragraphs per subsection.
- **Data (Section 3, pp. 4–5):** very short; missing key survey comparability and weighting details (see below).
- **Empirical Strategy (Section 4, pp. 5–6):** fine at a high level, but needs more depth on assumptions and diagnostics for staggered adoption.
- **Results (Section 5, pp. 6–9):** too thin for a main results section in a top journal; no deep exploration of mechanisms/heterogeneity beyond a small cohort table.
- **Discussion/Conclusion (Sections 6–7, pp. 9–10):** underdeveloped relative to the stakes.

**Figures**
- Figure 1 (p. 7–8) appears as a low-resolution inline plot. It has axes labels, but for publication quality you need:
  - clear coefficient markers,
  - legible fonts,
  - explicit definition of event time and omitted category,
  - *simultaneous* confidence bands or at least clear pointwise vs uniform distinction,
  - sample composition by event time (how many states contribute at each relative year).
- As provided, the figure is not publication quality.

**Tables**
- Tables 2–5 contain real numbers (no placeholders). Good.
- However: Table 4’s cohort “significance” flags are not enough—top journals want full inference details (CIs by cohort, multiple-testing adjustments, or at least a discussion).

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

On the narrow question “is the paper doing basic inference correctly?”, it is **mostly passing**, but there are still gaps that matter at the top-journal bar.

### (a) Standard errors
- Main estimates report **SEs in parentheses** (Table 3, p. 6; Table 5, p. 9). Pass.

### (b) Significance testing
- p-values are reported (Table 3). Pass.

### (c) Confidence intervals
- 95% CIs are reported for the main estimate (Table 3). Pass.

### (d) Sample sizes
- N is reported for key tables (e.g., Table 3 and Table 5). Pass at a minimum level.
- But: you do not show Ns for each event-time coefficient (how many treated observations identify each lead/lag). This is increasingly expected because staggered designs can have thin support at long lags.

### (e) DiD with staggered adoption
- You use **Callaway & Sant’Anna (2021)** with not-yet-treated controls (Section 4.2, p. 6). This is the correct direction and avoids the classic TWFE contamination. Pass.
- However, a top-journal paper should also:
  - report sensitivity to alternative modern estimators (Sun & Abraham; Borusyak et al.),
  - clarify whether you use **never-treated + not-yet-treated** and what happens when support shrinks,
  - discuss *which* states identify *which* comparisons (Goodman-Bacon decomposition intuition, even if not TWFE-estimated).

### (f) RDD
- Not applicable.

**Bottom line on methodology:** not “unpublishable” on inference grounds (you do report SEs/CIs and use an appropriate staggered DiD estimator), but the econometric presentation is **not** at top-journal completeness.

---

# 3. IDENTIFICATION STRATEGY

### Core concern: Outcome mismatch + attenuation bias
Your outcome is **lifetime** depression diagnosis prevalence (a stock). This is not a clean proxy for “access” in the short 2011–2019 window because:
- A parity law plausibly affects **flows** (new diagnoses, utilization, visit modality), not the cumulative stock.
- The stock changes slowly and is heavily driven by historical diagnosis patterns and demographic composition.
- In the presence of measurement error and compositional shifts, you can easily get near-zero or even negative movements unrelated to access.

This is not a minor point—it is likely the central reason your ATT is near zero.

### Parallel trends and diagnostics
- You report an event study with small, insignificant pre-trends (Section 5.2; Figure 1, pp. 7–8). That is necessary, but not sufficient.
- Given the outcome is a slow-moving stock, “flat pre-trends” are not very informative; many confounds could still exist without showing up as sharp differential pre-trends.

### Major omitted confounders/policy bundling (pre-COVID)
Between 2011–2019, mental health diagnosis and access were affected by many state-varying forces likely correlated with telehealth parity adoption:
- ACA Medicaid expansion and Marketplace dynamics (2014 onward),
- state mental health parity enforcement, network adequacy rules,
- opioid crisis responses and behavioral health funding,
- changes in scope-of-practice, telehealth modality rules, and cross-state licensing,
- broadband rollout and rural health initiatives,
- insurer and provider market structure trends.

The paper currently does not seriously confront “policy soup” endogeneity. A top-journal referee will ask: **why did states adopt parity when they did?** If adoption is correlated with unobserved changes in mental health systems, your DiD can be biased even with modern estimators.

### Treatment definition and heterogeneity
- You code a state “treated” if the law is in effect for the full calendar year (Section 3.2, p. 5). This can introduce:
  - mis-timing (laws effective mid-year),
  - anticipation (providers/insurers adjust before full-year effective dates),
  - heterogeneity (coverage parity vs payment parity vs modality restrictions).
- Collapsing all parity laws to a single binary variable is likely too crude; it blurs mechanisms and attenuates effects.

### External validity and “always-treated”
- You exclude pre-2012 adopters from identification (noted throughout; e.g., Section 4.2 p. 6; Table 3 notes). That is correct mechanically, but it means your result is about **late adopters only**—a selected set of states. This further complicates interpretation.

### Placebos and robustness
You have some robustness checks (Table 5, p. 9), but they are not the kind of robustness a top journal expects:
- No **negative-control outcomes** (e.g., diabetes diagnosis prevalence, arthritis, etc.) to detect spurious “health diagnosis” reporting effects.
- No **policy-placebo timing** (randomized adoption years) or permutation inference.
- No **border discontinuity / adjacent-state** comparison to address regional shocks.
- No exploration of **heterogeneity predicted by mechanism** (rurality, broadband, provider shortage areas, baseline telehealth penetration, share in self-insured ERISA plans).

### Do conclusions follow?
Your conclusion—“parity laws alone may have limited effects”—is plausible, but the evidence as currently constructed supports a narrower statement:
- “We do not detect an effect on *lifetime depression diagnosis prevalence* in BRFSS among late-adopting states, 2011–2019.”
That is not the same as “no effect on access.” The paper currently over-interprets the null.

---

# 4. LITERATURE (missing references + BibTeX)

## (A) Modern DiD / event-study essentials you should cite and engage
You cite Callaway & Sant’Anna, Goodman-Bacon, and de Chaisemartin & D’Haultfoeuille—good. But for a top-journal paper you should also position your empirical implementation relative to:

1) **Sun & Abraham (2021)** (interaction-weighted event studies; widely used)
```bibtex
@article{SunAbraham2021,
  author  = {Sun, Liyang and Abraham, Sarah},
  title   = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {175--199}
}
```

2) **Borusyak, Jaravel & Spiess (2021)** (imputation estimator; clarifies identifying variation)
```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year    = {2021}
}
```
*(If you prefer only peer-reviewed, cite the later published version if/when you update.)*

3) **Roth (2022)** on pretrend testing and sensitivity
```bibtex
@article{Roth2022,
  author  = {Roth, Jonathan},
  title   = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year    = {2022},
  volume  = {4},
  number  = {3},
  pages   = {305--322}
}
```

4) **Manski-style partial identification / sensitivity** is increasingly common for nulls; at least discuss.
(If you do not want to go that far, you should still do more than a single event-study plot.)

## (B) Telehealth policy + reimbursement literature (your domain positioning is thin)
The current references (Mehrotra et al.; Barnett et al.) are good descriptive anchors, but you need to engage more directly with:
- empirical work on **telehealth reimbursement/payment parity** and utilization,
- provider supply responses,
- mental health teletherapy expansion pre-COVID (even if limited).

I cannot recommend specific additional papers with full confidence without seeing your exact policy definition and without risking citation errors, but at a minimum you should add and synthesize:
- review and policy pieces documenting how **payment parity** vs **coverage parity** differentially affects adoption (many states adopted coverage-only first),
- empirical evidence on tele-mental-health adoption patterns in commercial insurance and Medicaid pre-COVID,
- work on ERISA and state mandate “bite” (how much of the insured market is affected).

## (C) BRFSS comparability / measurement (currently ignored)
A serious paper using BRFSS over time should cite and discuss the **2011 BRFSS methodological changes** (cell phone inclusion, raking weights) and what that implies for comparability even within 2011–2019 across states. Add CDC documentation and/or methodological papers and explicitly state:
- whether you use BRFSS weights,
- whether the outcome is age-adjusted,
- how you handle changing state sampling frames.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets (fails top-journal standard in multiple places)
- Section 2.3 (p. 4) and Section 6 (pp. 9–10) read like policy notes. Top journals want fully developed paragraphs with claims, evidence, and transitions.
- Your discussion section should not be a list of possible explanations; it should adjudicate between them using data, heterogeneity, or external evidence.

### Narrative flow
- The introduction (pp. 1–2) is serviceable but not compelling enough for AER/QJE/JPE/ReStud. It needs:
  - a sharper motivating fact,
  - a clear conceptual mechanism (coverage mandate → reimbursement certainty → provider adoption → diagnosis/treatment),
  - a precise statement of why the question is unresolved given existing evidence,
  - and a preview of *why a null is informative* and what it rules out.

### Sentence-level writing
- Writing is clear but generic. Many sentences are “telehealth has potential…” style. A top journal expects tighter writing, more concrete claims, and more quantified magnitudes.

### Accessibility and magnitudes
- You report an ATT in percentage points, but you do not benchmark it:
  - relative to mean 19% prevalence (Table 2), −0.48 pp is about −2.5% of the mean.
  - Is a 1 pp change plausible? What does it translate to in number of adults?
- You include an MDE calculation (Section 4.3), which is good, but you should interpret the CI in terms of policy relevance: what effects are ruled out?

### Figures/tables quality
- Table notes are decent. But Figure 1 needs publication-grade formatting and documentation (who contributes at each event time; pointwise vs uniform bands; estimator details).

---

# 6. CONSTRUCTIVE SUGGESTIONS (how to make this publishable/impactful)

## A. Fix the outcome problem (highest priority)
If the goal is “access to mental health care,” lifetime depression diagnosis prevalence is a weak and slow-moving proxy. You need to add outcomes that are closer to the mechanism:

1) **Flow/access measures in BRFSS** (if available consistently):
- “Poor mental health days” (mentally unhealthy days in past 30 days),
- measures of having a personal doctor, unmet care due to cost,
- insurance coverage status (to restrict to privately insured),
- possibly “received counseling/therapy” if available (often not consistently).

2) **Claims-based utilization data** (preferred for top journals):
- commercial claims (telehealth visits, mental health outpatient visits),
- Marketplace claims or APCD (where available),
- Medicare (less relevant to private parity laws but useful for placebo/contrast),
- Medicaid (again not directly treated by private parity, but many states changed telehealth Medicaid rules too—important confound).

A top-journal version likely requires claims or provider-side data. With BRFSS alone, the contribution is likely too small.

## B. Use treatment heterogeneity: coverage parity vs payment parity, modalities
Right now “telehealth parity” is a single indicator. At minimum, split by:
- **payment parity** vs **coverage parity only**,
- whether **audio-only** is allowed (pre-COVID often restricted),
- whether mental health services are explicitly covered,
- enforcement strength / effective dates.

This is essential to interpret nulls: a “coverage-only” law with low reimbursement may do little; that is not informative about true parity.

## C. Strengthen identification beyond baseline DiD
Add designs/analyses that make parallel trends more credible:

1) **Border-county design** (if you can move to county-level outcomes or use restricted BRFSS micro):
- Compare counties near state borders with different adoption timing.
- Controls for regional shocks.

2) **Triple differences** using groups differentially exposed:
- Privately insured (treated) vs self-insured ERISA-heavy sectors (less treated) if you can approximate,
- Rural vs urban (telehealth more valuable where distance is greater),
- Areas with low psychiatrist supply (larger expected effect).

3) **Policy controls / stacked DiD**
- Control for Medicaid expansion, broadband grants, mental health workforce policies, and other contemporaneous telehealth rules.
- Consider a “stacked” DiD/event-study sample approach for cleaner comparisons.

4) **Randomization inference / permutation tests**
- Especially important for null results and for the suspicious “significant” negative cohort effects in 2017 and 2019 (Table 4, p. 8) that look like idiosyncratic shocks.

## D. Investigate and explain the negative cohort effects (Table 4)
Your 2017 and 2019 cohorts show large negative effects with 1 state each. That screams “state-specific shock” or “model artifact,” not a causal effect of parity reducing diagnoses.
- Show which states these are **explicitly** in the table.
- Plot raw trends for those states vs donor pool.
- Do leave-one-out sensitivity: does the overall ATT move when each late-adopting state is dropped?

## E. BRFSS measurement/weighting and compositional adjustment
At minimum:
- Clarify whether state-year prevalence is computed using BRFSS survey weights.
- Age-standardize prevalence (common in public health; matters for state composition).
- Consider micro-level estimation with individual controls + state and year FE, then aggregate to group-time effects (or at least show composition stability).

## F. Rewrite and expand (this is not a minor edit)
To meet top-journal standards, you need:
- a real literature review section (not scattered citations),
- a richer institutional section with legally precise definitions and examples,
- a more serious threats-to-identification section,
- appendices with policy coding, alternative event-study estimators, placebo outcomes, and heterogeneity.

---

# 7. OVERALL ASSESSMENT

## Strengths
- Uses an appropriate modern staggered DiD estimator (Callaway–Sant’Anna) rather than naive TWFE (Section 4.2, p. 6; Table 3, p. 6).
- Reports SEs, p-values, and CIs (Table 3).
- Transparent about always-treated states not identifying effects (throughout; e.g., Table 1 note, p. 3).

## Critical weaknesses (why it would be rejected at top journals)
1) **Outcome is not well aligned with the mechanism** (lifetime diagnosis stock), making null results hard to interpret as “no effect on access.”
2) **Identification is not sufficiently defended** against confounding policy changes and endogenous adoption timing.
3) **Binary treatment coding ignores crucial heterogeneity** (coverage vs payment parity; modalities; enforcement), likely attenuating effects.
4) **Manuscript is far too short** (~13 pages) and not written at a top-journal narrative standard (bullets; memo-like discussion).
5) The “significant” negative late-cohort effects are not diagnosed, threatening credibility.

## Specific improvements (minimum to resubmit somewhere serious)
- Replace/add outcomes (utilization/flows), add treatment heterogeneity, strengthen design (border/DDD), expand writing and appendices, and provide richer measurement detail for BRFSS.

---

DECISION: REJECT AND RESUBMIT